Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PEOPLE - Changes at St Jude Medical:

This article was originally published in Clinica

Executive Summary

St Jude Medical has announced the creation of two new divisions by the end of the year: cardiology and atrial fibrillation. The cardiology division will be led by Paul Buckman, who has previously served for Boston Scientific. The atrial fibrillation division will be led by Jane Song, who steps down as president of the cardiac surgery division, and was previously senior vice-president of operations for the cardiac rhythm management unit. The St Paul, Minnesota-based firm has also named Ms Song's successor, George Fazio, president of St Jude's Europe division, who joined the company in 1992. The vice-president for northern Europe and Africa, Denis Gestin, will succeed Mr Fazio. Mr Gestin also previously managed the firm's subsidiary in France.

You may also be interested in...



Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines

Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.

Indian Telemedicine Prospects Boosted By Long-Awaited Guidelines

Guidelines outline permitted practices and patient safeguards for both physicians and technology platforms.

COVID-19 Vaccines Are Coming Soon, But Therapeutics Needed Now

Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.

Topics

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel